- Doctors & Departments
- Conditions & Advice
- Your Visit
- Research & Innovation
Cystic fibrosis (CF) is a genetic disease that causes persistent lung infections, making it difficult for patients to breathe. According to the Cystic Fibrosis Foundation, more than 30,000 people in the United States — and more than 70,000 people worldwide — are living with the disease.
In the lungs of patients with CF, mucus clogs the airways and traps bacteria. The pathogens most frequently cultured from CF airway samples are Pseudomonas aeruginosa and Staphylococcus aureus. These "traditional" CF bacteria are associated with chronic airway infection, inflammation and pulmonary decline.
Recent molecular DNA sequencing efforts have revealed that bacterial communities in CF airways are more complex, but most studies have evaluated sputum (coughed-up mucus), which contains a mix of lower and upper airway bacteria. Bronchoscopy with bronchoalveolar lavage fluid (BALF) collection is preferred for studying lower airway bacteria with minimal upper airway contamination, but routine surveillance bronchoscopy is not recommended for CF patients.
Defining bacterial communities in CF — and distinguishing pathogenic bacteria that cause disease from commensal (not harmful) bacteria — is important for developing new treatment strategies for CF.
Edith Zemanick, MD, and other researchers at the Mike Morris Cystic Fibrosis Research and Care Center in the Breathing Institute at Children’s Hospital Colorado, led a multi-center study to evaluate the CF airway microbiome in BALF samples from CF patients of all ages and disease severity.
The following is a summary of the study participants and procedures of the study.
The most common indications for bronchoscopy in CF patients were persistent cough (41 percent), unresponsiveness to treatment (29 percent), need for lower airway culture (27 percent), concurrent surgery (21 percent) and lung function decline (8 percent).
The most common indications for bronchoscopy in disease control patients were asthma or wheezing (38 percent), pneumonia/recurrent pneumonia (36 percent), dysphagia/esophageal reflux (33 percent) and chronic cough (24 percent).
BALF bacterial cultures were positive in 90 percent of adult CF, 70 percent of pediatric CF and 33 percent of disease control participants. The total bacterial load (TBL) was higher in pediatric CF compared with disease control samples. TBL did not differ between adult and pediatric CF. Bacterial populations were more diverse in disease control compared with CF participants.
Traditional CF pathogens (Pseudomonas, Staphylococcus, Stenotrophomonas, Haemophilus, Achromobacter and Burkholderia) were the dominant bacterial populations in 47 percent of pediatric CF and 60 percent of adult CF BALF samples. None of these bacterial populations were dominant in disease control samples.
Interestingly, 20 percent of pediatric and adult CF BALF contained a dominant bacterium with an unknown association to disease severity and progression in CF, which the authors termed "non-traditional" (Streptococcus, Prevotella, Bordetella, Veillonella, Moraxella, Neisseria and Corynebacterium).
TBL did not differ across CF age groups, but bacterial diversity was higher in younger age groups. The non-traditional bacterium Streptococcus was most prominent in young children with CF, and traditional CF bacteria comprised less than 50 percent of the bacterial community in children under age 2. By age 6, a median of 70 percent of the bacterial communities consisted of traditional CF pathogens.
Non-traditional bacteria (Streptococcus, Veillonella and Prevotella) were associated with decreased markers of airway inflammation. Pseudomonas aeruginosa abundance and markers of inflammation were higher in CF patients with pulmonary exacerbation compared with clinically stable participants.
This large, multi-center study demonstrated that lower airway bacteria in patients with CF differ by patient age. Non-traditional bacteria (Streptococcus, Veillonella, Prevotella and Haemophilus) were more abundant in younger children and decreased in abundance in older patients. Bacterial diversity in younger patients was associated with less airway inflammation.
Traditional CF bacteria (Pseudomonas) became increasingly abundant as patients got older. Bacterial diversity was lower in older CF patients, due to the prominence of Pseudomonas, and airway inflammation increased. Types of bacteria did not differ between CF patients who were clinically stable and those who had respiratory symptoms.
The clinical impact of non-traditional bacteria in CF is still under investigation. These bacteria may be less pro-inflammatory than traditional CF bacteria. Understanding the diverse non-traditional bacterial communities in young CF patients and how those communities change as traditional CF bacteria become more abundant may improve early treatments.
The Mike McMorris Cystic Fibrosis Research and Care Center in the Breathing Institute at Children's Hospital Colorado is one of the premiere cystic fibrosis (CF) clinical care and research centers in the country.